GPT and neutropenia: Similarly, there was a lower percentage of patients with AEs leading to dose adjustment/interruption with asciminib (33.3%) than imatinib (62.5%) and 2G TKI (66.7%); these were mainly hematological for asciminib (neutropenia, n = 4; thrombocytopenia, n = 3) and imatinib (neutropenia, n = 2; leukopenia, n = 2), and for 2G TKI were diarrhea and alanine aminotransferase increased (n = 2 each).